Regeneron Pharmaceuticals Stock Drops 7.47% Despite FDA Approval and Clinical Trial Success

On May 6, 2025, Regeneron Pharmaceuticals (REGN) saw a trading volume of $808 million, ranking 77th in the day's stock market activity. The company's stock price fell by 7.47%, marking the second consecutive day of decline, with a total decrease of 7.78% over the past two days.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Eylea (aflibercept) for the treatment of diabetic retinopathy. This approval is a significant milestone for the company, as it expands the indications for Eylea, which is already approved for the treatment of wet age-related macular degeneration and macular edema following retinal vein occlusion.

Regeneron Pharmaceuticals, Inc. (REGN) has reported positive results from a Phase 3 clinical trial of its investigational drug, REGN3500, for the treatment of severe asthma. The trial met its primary endpoint, demonstrating a statistically significant reduction in the rate of asthma exacerbations compared to placebo. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2025.

Regeneron Pharmaceuticals, Inc. (REGN) has entered into a strategic collaboration with Sanofi (SNY) to develop and commercialize a new class of bispecific antibodies for the treatment of cancer. The collaboration will leverage Regeneron's proprietary VelociSuite technologies and Sanofi's expertise in oncology drug development. The companies will share development costs and profits equally.